Differing Perspectives on Roche/Genentech Biologic Manufacturing
This article was originally published in RPM Report
Executive Summary
FDA has raised questions about manufacturing and quality control during the review of two recently approved Roche/Genentech cancer drugs. At the same time, Roche is highlighting its leading presence and competency in biologics manufacturing as a core asset for the company.